Can You Get the MMR Vaccine While Taking Cosentyx?
No, you should not receive the live MMR (measles, mumps, rubella) vaccine while on Cosentyx (secukinumab). Cosentyx suppresses the immune system by blocking IL-17A, which increases risks from live vaccines like MMR. Official guidance from Novartis and the FDA recommends avoiding live vaccines during treatment and for up to 4-6 weeks after the last dose.[1][2]
What Happens If You Get It Anyway?
Live vaccines can replicate uncontrollably in immunocompromised patients, potentially causing vaccine-derived infections such as measles or rubella. Case reports with similar biologics show rare but serious outcomes like disseminated varicella. Consult your doctor immediately if vaccinated unknowingly; they may monitor or test for replication.[3]
Which Vaccines Are Safe on Cosentyx?
Inactivated or recombinant vaccines are generally safe and recommended, including:
- Influenza (injected, not nasal spray)
- Tdap (tetanus, diphtheria, pertussis)
- Pneumococcal
- Shingles (Shingrix, recombinant)
- COVID-19 vaccines
Get these before starting Cosentyx if possible. Annual flu shots remain advised yearly.[1][4]
Timing: When Can You Safely Get Live Vaccines?
Finish MMR or other live vaccines (e.g., varicella, oral polio, yellow fever) at least 4 weeks before starting Cosentyx. After stopping, wait 4-6 weeks minimum, though some experts suggest longer (up to 3 months) based on drug clearance half-life of about 27 days.[2][5]
| Vaccine Type | Safe on Cosentyx? | Notes |
|--------------|-------------------|--------|
| Live (MMR, varicella) | No | Avoid during and shortly after treatment |
| Inactivated (flu shot, HPV) | Yes | Preferred; boost as needed |
| Subunit/recombinant (Shingrix) | Yes | No replication risk |
Doctor and Patient Advice
Always discuss with your rheumatologist or prescriber—they'll weigh risks based on your condition (e.g., psoriasis, psoriatic arthritis). If unvaccinated against MMR, prioritize it pre-treatment. Pregnancy or travel may require alternatives like immune globulin for measles exposure.[1][6]
Sources
[1]: Cosentyx Prescribing Information (Novartis FDA label)
[2]: CDC Guidelines on Immunization and Biologics
[3]: Live Vaccine Risks in IL-17 Inhibitors (PubMed review)
[4]: ACR Vaccination Guidance for Rheumatic Diseases
[5]: Secukinumab Pharmacokinetics (FDA review)
[6]: Novartis Cosentyx HCP Site